Alliance Global Partners lowered the firm’s price target on PDS Biotechnology (PDSB) to $4.50 from $7 and keeps a Buy rating on the ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Immutep (IMMP) stock climbed 11% Thursday after the company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Read more here.

AEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The ...

Immutep (IMMP) announces positive data from investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA and chemotherapy for first-line treatment ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...